Abstract
The lipid nanoparticle (LNP) is one of the promising nanotechnologies for the delivery of RNA molecules, such as small interfering RNA (siRNA) and messenger RNA (mRNA). A series of LNPs that contain an mRNA encoding the antigen protein of SARS-CoV-2 were already approved as RNA vaccines against this infectious disease. Since LNP formulations are generally metastable, their physicochemical properties are expected to shift toward a more stable state during the long-time storage of suspensions. The current mRNA vaccines are supplied in the form of frozen formulations with a cryoprotectant for preventing deterioration. They must be stored in a freezer at temperatures from −80 °C to −15 °C. It is thought that therapeutic applications of this mRNA-LNP technology could be accelerated if a new formulation that permits mRNA-LNPs to be stored under milder conditions were available. We previously reported on a one-pot method for producing siRNA-encapsulated LNPs by combining freeze-drying technology with the conventional alcohol dilution method (referred to herein as the “alcohol dilution–lyophilization method”). In this study, this method was applied to the preparation of mRNA-LNPs to provide a freeze-dried formulation of mRNA LNPs. The resulting formulation can be stored at 4 °C for at least 4 months.
Funding Information
  • JSPS KAKENHI (18K18377, 21K18035, 20H00657, 21K18320, JPMJCR17H1)
  • Kato Memorial Bioscience Foundation (18K18377, 21K18035, 20H00657, 21K18320, JPMJCR17H1)
  • Japan Science and Technology Agency (18K18377, 21K18035, 20H00657, 21K18320, JPMJCR17H1)
  • Asahi Glass Foundation (18K18377, 21K18035, 20H00657, 21K18320, JPMJCR17H1)
  • NOF CORPORATION (18K18377, 21K18035, 20H00657, 21K18320, JPMJCR17H1)

This publication has 36 references indexed in Scilit: